What is Artemis?
Artemis distinguishes itself in the crowded wellness sector by integrating deep scientific inquiry with a mission-driven approach to the cannabis industry. By leveraging the expertise of Chief Medical Advisor Dr. Junella Chin, the company focuses on the pharmacokinetics of CBD, ensuring that its product curation is backed by clinical understanding rather than mere trend-following. Beyond its product library, Artemis serves as a platform for advocacy, actively supporting BIPOC-owned brands and championing legislative reform to address the historical inequities associated with marijuana criminalization. This dual-pronged strategy of scientific efficacy and social responsibility positions the company as a thought leader in the evolving landscape of plant-based therapeutics.
How much funding has Artemis raised?
Artemis has raised a total of $500K across 1 funding round:
Debt
$500K
Debt (2025): $500K with participation from City National Bank of Florida
Key Investors in Artemis
City National Bank of Florida
A prominent financial institution providing specialized banking services and debt financing solutions to support the growth of established enterprises.
What's next for Artemis?
With this major enterprise-level funding, Artemis is well-positioned to scale its operations and deepen its research capabilities. The strategic allocation of this capital will likely focus on expanding its curated collection of CBD products while enhancing its educational infrastructure, including its podcast and article series. As the regulatory environment for cannabis and CBD continues to shift, Artemis is poised to leverage its scientific credibility to capture a larger share of the wellness market. Future growth will likely involve strengthening supply chain partnerships and further integrating its advocacy initiatives into its core business model, ensuring that the company remains at the forefront of both therapeutic innovation and social impact within the botanical wellness space.
See full Artemis company page
